QQQ   313.68 (+0.27%)
AAPL   122.64 (+1.36%)
MSFT   231.59 (+1.14%)
FB   258.16 (+1.36%)
GOOGL   2,020.11 (+0.21%)
AMZN   3,059.42 (+0.07%)
TSLA   674.15 (-1.18%)
NVDA   540.93 (+1.62%)
BABA   239.25 (-0.39%)
CGC   32.87 (-1.02%)
GE   12.47 (-2.27%)
MU   89.05 (+1.06%)
NIO   45.37 (-3.08%)
AMD   83.77 (+1.64%)
T   28.46 (-0.59%)
F   11.62 (-1.19%)
ACB   10.84 (+0.18%)
DIS   186.55 (-2.32%)
BA   212.90 (-1.64%)
NFLX   541.68 (-0.92%)
BAC   34.78 (-3.20%)
QQQ   313.68 (+0.27%)
AAPL   122.64 (+1.36%)
MSFT   231.59 (+1.14%)
FB   258.16 (+1.36%)
GOOGL   2,020.11 (+0.21%)
AMZN   3,059.42 (+0.07%)
TSLA   674.15 (-1.18%)
NVDA   540.93 (+1.62%)
BABA   239.25 (-0.39%)
CGC   32.87 (-1.02%)
GE   12.47 (-2.27%)
MU   89.05 (+1.06%)
NIO   45.37 (-3.08%)
AMD   83.77 (+1.64%)
T   28.46 (-0.59%)
F   11.62 (-1.19%)
ACB   10.84 (+0.18%)
DIS   186.55 (-2.32%)
BA   212.90 (-1.64%)
NFLX   541.68 (-0.92%)
BAC   34.78 (-3.20%)
QQQ   313.68 (+0.27%)
AAPL   122.64 (+1.36%)
MSFT   231.59 (+1.14%)
FB   258.16 (+1.36%)
GOOGL   2,020.11 (+0.21%)
AMZN   3,059.42 (+0.07%)
TSLA   674.15 (-1.18%)
NVDA   540.93 (+1.62%)
BABA   239.25 (-0.39%)
CGC   32.87 (-1.02%)
GE   12.47 (-2.27%)
MU   89.05 (+1.06%)
NIO   45.37 (-3.08%)
AMD   83.77 (+1.64%)
T   28.46 (-0.59%)
F   11.62 (-1.19%)
ACB   10.84 (+0.18%)
DIS   186.55 (-2.32%)
BA   212.90 (-1.64%)
NFLX   541.68 (-0.92%)
BAC   34.78 (-3.20%)
QQQ   313.68 (+0.27%)
AAPL   122.64 (+1.36%)
MSFT   231.59 (+1.14%)
FB   258.16 (+1.36%)
GOOGL   2,020.11 (+0.21%)
AMZN   3,059.42 (+0.07%)
TSLA   674.15 (-1.18%)
NVDA   540.93 (+1.62%)
BABA   239.25 (-0.39%)
CGC   32.87 (-1.02%)
GE   12.47 (-2.27%)
MU   89.05 (+1.06%)
NIO   45.37 (-3.08%)
AMD   83.77 (+1.64%)
T   28.46 (-0.59%)
F   11.62 (-1.19%)
ACB   10.84 (+0.18%)
DIS   186.55 (-2.32%)
BA   212.90 (-1.64%)
NFLX   541.68 (-0.92%)
BAC   34.78 (-3.20%)
Log in
NASDAQ:GWPH

GW Pharmaceuticals Stock Forecast, Price & News

$214.22
-0.63 (-0.29 %)
(As of 02/26/2021 10:29 AM ET)
Add
Compare
Today's Range
$213.87
Now: $214.22
$215.46
50-Day Range
$125.40
MA: $172.01
$215.00
52-Week Range
$67.98
Now: $214.22
$217.50
Volume35,669 shs
Average Volume1.19 million shs
Market Capitalization$6.65 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.15
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, Dravet syndrome, and Lennox-Gastaut syndrome, as well as in phase III clinical trials for the treatment of tuberous sclerosis complex. The company also develops and markets Sativex for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of for schizophrenia, autism spectrum disorder, and neonatal hypoxic ischemic encephalopathy. It primarily operates in Europe, the United Kingdom, the United States, and internationally. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.
GW Pharmaceuticals logo

Headlines

GW Pharmaceuticals: Q4 Earnings Insights
February 16, 2021 |  finance.yahoo.com
Jazz Inks $7.2B Deal To Buy GW Pharmaceuticals
February 4, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GWPH
CUSIPN/A
Phone44-12-2326-6800
Employees901
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$311.33 million
Cash Flow$0.01 per share
Book Value$23.48 per share

Profitability

Net Income$-9,020,000.00

Miscellaneous

Market Cap$6.65 billion
Next Earnings Date5/10/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.49 out of 5 stars

Medical Sector

450th out of 1,957 stocks

Pharmaceutical Preparations Industry

226th out of 771 stocks

Analyst Opinion: 2.1Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$214.22
-0.63 (-0.29 %)
(As of 02/26/2021 10:29 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GWPH News and Ratings via Email

Sign-up to receive the latest news and ratings for GWPH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











GW Pharmaceuticals (NASDAQ:GWPH) Frequently Asked Questions

Is GW Pharmaceuticals a buy right now?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GW Pharmaceuticals in the last twelve months. There are currently 10 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" GW Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GWPH, but not buy additional shares or sell existing shares.
View analyst ratings for GW Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than GW Pharmaceuticals?

Wall Street analysts have given GW Pharmaceuticals a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but GW Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting GW Pharmaceuticals?

GW Pharmaceuticals saw a drop in short interest in January. As of January 29th, there was short interest totaling 1,760,000 shares, a drop of 32.0% from the January 14th total of 2,590,000 shares. Based on an average daily trading volume, of 717,400 shares, the days-to-cover ratio is currently 2.5 days.
View GW Pharmaceuticals' Short Interest
.

When is GW Pharmaceuticals' next earnings date?

GW Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for GW Pharmaceuticals
.

How were GW Pharmaceuticals' earnings last quarter?

GW Pharmaceuticals plc (NASDAQ:GWPH) issued its quarterly earnings results on Tuesday, November, 3rd. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, topping analysts' consensus estimates of ($0.63) by $0.27. The biopharmaceutical company had revenue of $137.10 million for the quarter, compared to the consensus estimate of $97.66 million. GW Pharmaceuticals had a negative trailing twelve-month return on equity of 7.46% and a negative net margin of 11.05%. The firm's quarterly revenue was up 50.7% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.04) earnings per share.
View GW Pharmaceuticals' earnings history
.

How has GW Pharmaceuticals' stock price been impacted by Coronavirus?

GW Pharmaceuticals' stock was trading at $86.89 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, GWPH shares have increased by 146.5% and is now trading at $214.22.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for GWPH?

14 analysts have issued twelve-month target prices for GW Pharmaceuticals' shares. Their forecasts range from $128.00 to $275.00. On average, they anticipate GW Pharmaceuticals' share price to reach $197.31 in the next twelve months. This suggests that the stock has a possible downside of 7.9%.
View analysts' price targets for GW Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are GW Pharmaceuticals' key executives?

GW Pharmaceuticals' management team includes the following people:
  • Mr. Justin D. Gover, CEO & Exec. Director (Age 50, Pay $1.19M)
  • Mr. Scott M. Giacobello, Chief Financial Officer (Age 51, Pay $743.33k)
  • Mr. Douglas B. Snyder, Chief Legal Officer & Sec. (Age 57, Pay $787.02k)
  • Dr. Volker Knappertz M.D., D.Sc., Chief Medical Officer (Age 56, Pay $830.47k)
  • Mr. Christopher John Tovey, Chief Operating Officer (Age 56)
  • Mr. Stephen D. Schultz, VP of Investor Relations
  • Kristen Cardillo, VP of Corp. Communication
  • Ms. Tina St. Leger, Chief HR Officer
  • Prof. Ben Whalley, Head of Discovery Research
  • Mr. Darren S. Cline, U.S. Chief Commercial Officer (Age 57)

What is Justin Gover's approval rating as GW Pharmaceuticals' CEO?

14 employees have rated GW Pharmaceuticals CEO Justin Gover on Glassdoor.com. Justin Gover has an approval rating of 80% among GW Pharmaceuticals' employees.

Who are some of GW Pharmaceuticals' key competitors?

What other stocks do shareholders of GW Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GW Pharmaceuticals investors own include (CGC), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Tesla (TSLA), Intel (INTC), Netflix (NFLX), Gilead Sciences (GILD), Aurora Cannabis (ACB) and Advanced Micro Devices (AMD).

What is GW Pharmaceuticals' stock symbol?

GW Pharmaceuticals trades on the NASDAQ under the ticker symbol "GWPH."

Who are GW Pharmaceuticals' major shareholders?

GW Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Janus Henderson Group PLC (6.36%), Morgan Stanley (2.74%), Federated Hermes Inc. (2.33%), ETF Managers Group LLC (2.00%), M&G Investment Management Ltd. (1.65%) and Price T Rowe Associates Inc. MD (1.64%). Company insiders that own GW Pharmaceuticals stock include Adam D George, Cabot Brown, Catherine J Mackey, Christopher J Tovey, Douglas B Snyder, Geoffrey W Dr Guy, James Noble, Julian S Gangolli, Justin D Gover, Scott M Giacobello, Volker Knappertz and William A Waldegrave.
View institutional ownership trends for GW Pharmaceuticals
.

Which institutional investors are selling GW Pharmaceuticals stock?

GWPH stock was sold by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Victory Capital Management Inc., Clough Capital Partners L P, Janus Henderson Group PLC, Hardman Johnston Global Advisors LLC, Baker BROS. Advisors LP, M&G Investment Management Ltd., and BlackRock Inc.. Company insiders that have sold GW Pharmaceuticals company stock in the last year include Adam D George, Christopher J Tovey, Douglas B Snyder, Geoffrey W Dr Guy, Justin D Gover, Scott M Giacobello, and Volker Knappertz.
View insider buying and selling activity for GW Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying GW Pharmaceuticals stock?

GWPH stock was purchased by a variety of institutional investors in the last quarter, including ETF Managers Group LLC, Renaissance Technologies LLC, Brown Capital Management LLC, Tri Locum Partners LP, Price T Rowe Associates Inc. MD, Jennison Associates LLC, Penserra Capital Management LLC, and Candriam Luxembourg S.C.A..
View insider buying and selling activity for GW Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of GW Pharmaceuticals?

Shares of GWPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is GW Pharmaceuticals' stock price today?

One share of GWPH stock can currently be purchased for approximately $214.22.

How much money does GW Pharmaceuticals make?

GW Pharmaceuticals has a market capitalization of $6.65 billion and generates $311.33 million in revenue each year. The biopharmaceutical company earns $-9,020,000.00 in net income (profit) each year or ($0.24) on an earnings per share basis.

How many employees does GW Pharmaceuticals have?

GW Pharmaceuticals employs 901 workers across the globe.

What is GW Pharmaceuticals' official website?

The official website for GW Pharmaceuticals is www.gwpharm.com.

Where are GW Pharmaceuticals' headquarters?

GW Pharmaceuticals is headquartered at SOVEREIGN HOUSE VISION PARK HISTON, CAMBRIDGE X0, CB24 9BZ.

How can I contact GW Pharmaceuticals?

GW Pharmaceuticals' mailing address is SOVEREIGN HOUSE VISION PARK HISTON, CAMBRIDGE X0, CB24 9BZ. The biopharmaceutical company can be reached via phone at 44-12-2326-6800 or via email at [email protected]


This page was last updated on 2/26/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.